--- title: "U.S. Stock Market Midday Update: MDxHealth down 12.9% with no negative news? Unusual capital movement raises questions, increased volatility needs observation" type: "News" locale: "en" url: "https://longbridge.com/en/news/296259716.md" description: "MDxHealth SA fell 12.90%; AbbVie rose 2.75%, with a transaction volume of USD 599 million; Amgen rose 1.55%, with a transaction volume of USD 547 million; Gilead Sciences rose 3.22%, with a transaction volume of USD 427 million; Vertex Pharmaceuticals rose 2.62%, with a market value of USD 134.1 billion" datetime: "2026-08-18T18:33:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296259716.md) - [en](https://longbridge.com/en/news/296259716.md) - [zh-HK](https://longbridge.com/zh-HK/news/296259716.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: MDxHealth down 12.9% with no negative news? Unusual capital movement raises questions, increased volatility needs observation **U.S. Stock Market Midday Update** MDxHealth SA, down 12.90%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie up 2.75%. Based on recent key news: 1. On August 18, Haisco and AbbVie reached a cooperation agreement, granting AbbVie exclusive rights to develop, produce, and commercialize globally, with a potential total deal amount exceeding $700 million. This news drove AbbVie's stock price up. 2. On August 18, AbbVie announced a third-quarter dividend, with shareholders set to receive a dividend of 0.38 Brazilian Reais per unit on August 20, which boosted investor confidence and promoted the stock price increase. 3. On August 17, analyst ratings indicated that AbbVie is currently rated as "Moderate Buy," but it is not included in the top recommended stocks list, with the market holding a cautious attitude towards its future performance. The pharmaceutical industry is facing intensified competition, and innovative drug companies are encountering challenges. Amgen up 1.55%. Based on recent key news: 1. On August 17, AstraZeneca announced the official launch of Tezspire injection in China. This drug was developed in collaboration with Amgen for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, driving Amgen's stock price up. 2. On August 17, Barclays raised Amgen's target price from $360 to $380, maintaining a neutral rating. The target price increase reflects market confidence in Amgen's future performance, promoting the stock price rise. 3. On August 17, MarketBeat reported that Amgen currently maintains a hold rating among analysts but is not included in the top recommended stocks list. Nevertheless, Amgen's stock price continues to perform well. The pharmaceutical industry is highly competitive, and the market is undergoing restructuring. Gilead Sciences up 3.22%. Based on recent key news: 1. On August 18, BMO Capital analyst Evan Seigerman reiterated a buy rating on Gilead Sciences, with a target price of $174. This rating boosted market confidence in the stock, driving the price up. 2. On August 18, a FactSet survey showed that analysts raised their median EPS estimate for Gilead Sciences for 2026 to -0.45, improving market expectations for its future profitability, which helped push the stock price up. 3. On August 19, Gilead Sciences CFO Andrew Dickinson plans to sell shares, with recent insider sales totaling over $10.6 million, affecting short-term market sentiment but failing to stop the stock price increase. The pharmaceutical industry has performed strongly recently, with significant capital inflow. **Stocks with High Market Capitalization in the Industry** Forte Pharmaceuticals up 2.62%. Based on recent key news: 1. On August 18, BMO Capital analyst Evan Seigerman maintained a buy rating on Vertex Pharmaceuticals and set a target price of $600. This move demonstrates market confidence in the company, driving up the stock price of Vertex Pharmaceuticals. According to TipRanks, Seigerman's recommended stocks have an average return of 10.7% and a success rate of 59.19%. Source: MarketBeat 2. On August 18, the animal health industry faced macroeconomic tightening pressures, causing Zoetis's stock price to drop to a 52-week low. Despite the launch of the new product Simparica Trio, cautious consumer spending led to a downward revision of the full-year outlook. This industry dynamic may impact Vertex Pharmaceuticals' market performance. Source: MarketBeat 3. On August 16, MarketBeat noted that Vertex Pharmaceuticals was not included in the list of five stocks recommended by top analysts, despite its rating being a moderate buy. This may have an indirect effect on market confidence in Vertex Pharmaceuticals. Source: MarketBeat Macroeconomic tightening affects the health industry ### Related Stocks - [MDXH.US](https://longbridge.com/en/quote/MDXH.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Ross Stores To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday](https://longbridge.com/en/news/296618142.md) - [Short Interest in MDxHealth SA (NASDAQ:MDXH) Increases By 88.5%](https://longbridge.com/en/news/282512060.md) - [MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/282435376.md) - [mdxhealth says Oxford GPS-ProMPT study on GPS mdx publishes in European Urology Oncology](https://longbridge.com/en/news/291143207.md) - [MDxHealth SA (NASDAQ:MDXH) Short Interest Down 73.9% in April](https://longbridge.com/en/news/284088006.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**